Schwab Charles Investment Management Inc. increased its holdings in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) by 124.7% in the 3rd quarter, Holdings Channel reports. The firm owned 65,477 shares of the medical instruments supplier’s stock after acquiring an additional 36,342 shares during the period. Schwab Charles Investment Management Inc.’s holdings in LeMaitre Vascular were worth $2,451,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. BNP Paribas Arbitrage SA boosted its holdings in LeMaitre Vascular by 11,612.5% during the second quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 3,716 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in LeMaitre Vascular by 181.2% during the third quarter. Victory Capital Management Inc. now owns 4,139 shares of the medical instruments supplier’s stock worth $155,000 after purchasing an additional 2,667 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in LeMaitre Vascular during the second quarter worth $137,000. LS Investment Advisors LLC boosted its holdings in LeMaitre Vascular by 41.8% during the third quarter. LS Investment Advisors LLC now owns 4,510 shares of the medical instruments supplier’s stock worth $169,000 after purchasing an additional 1,330 shares during the last quarter. Finally, Royce & Associates LP acquired a new position in LeMaitre Vascular during the second quarter worth $156,000. Institutional investors and hedge funds own 69.24% of the company’s stock.

A number of analysts have commented on LMAT shares. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research note on Thursday, December 28th. Canaccord Genuity reiterated a “hold” rating and issued a $30.00 price target on shares of LeMaitre Vascular in a research note on Monday, October 9th. BidaskClub cut shares of LeMaitre Vascular from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 27th. First Analysis cut shares of LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 price target for the company. in a research note on Friday, October 27th. Finally, Benchmark cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. LeMaitre Vascular has an average rating of “Hold” and an average target price of $32.20.

In other news, insider David B. Roberts sold 4,123 shares of the stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $32.14, for a total value of $132,513.22. Following the transaction, the insider now directly owns 24,482 shares of the company’s stock, valued at $786,851.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 23.70% of the stock is owned by corporate insiders.

Shares of LeMaitre Vascular Inc (NASDAQ LMAT) opened at $32.86 on Thursday. The company has a market cap of $630.73, a price-to-earnings ratio of 42.68, a price-to-earnings-growth ratio of 2.52 and a beta of 0.54. LeMaitre Vascular Inc has a 12 month low of $19.82 and a 12 month high of $39.88.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.05. The firm had revenue of $24.80 million during the quarter, compared to analysts’ expectations of $25.49 million. LeMaitre Vascular had a net margin of 15.81% and a return on equity of 16.16%. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 earnings per share. equities research analysts expect that LeMaitre Vascular Inc will post 0.84 earnings per share for the current fiscal year.

WARNING: “Schwab Charles Investment Management Inc. Acquires 36,342 Shares of LeMaitre Vascular Inc (LMAT)” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://theolympiareport.com/2018/01/18/schwab-charles-investment-management-inc-acquires-36342-shares-of-lemaitre-vascular-inc-lmat.html.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.